2022

14/12/2022

UK NICE publishes Medtech Innovation Briefing on PromarkerD

24/11/2022

AGM Chairman’s Address and Investor Presentation

11/11/2022

PromarkerD patent granted in Hong Kong

04/11/2022

Investor Presentation to the Emerging ASX Gems Conference

03/11/2022

Proteomics International to present at the Emerging ASX Gems Conference

31/10/2022

October Newsletter 2022

20/10/2022

Precision diagnostics facility receives $2m funding boost

17/10/2022

Proteomics receives R&D tax incentive – AuManufacturing

17/10/2022

Proteomics receives $1.7 million in R&D tax incentive

29/09/2022

Cancer test boosts market hopes for Proteomics – The West Australian

27/09/2022

New Oesophageal Cancer Diagnostic shows strong performance

29/08/2022

Proteomics International develops non-invasive blood-based diagnostic for endometriosis – Clarivate BioWorld™

29/08/2022

Proteomics International Laboratories set to expand its commercial footprint in the US [VIDEO] – Proactive Investors

29/08/2022

Proteomics, UWA join forces on new diagnostic test – The West Australian

29/08/2022

OxiDx launched to maximise oxidative stress technology

15/08/2022

Proteomics International raises $8m in highly successful Placement

09/08/2022

Proteomics International signs binding letter of intent with Sonic Healthcare USA to take PromarkerD into the US market

02/08/2022

American doctors give tick to Proteomics kidney test – The West Australian

02/08/2022

Clinical Utility Study demonstrates PromarkerD test benefits

01/08/2022

Potential breakthrough blood test able to detect people with endometriosis

01/08/2022

Boost for Proteomics in fight against painful disorder – The West Australian

31/07/2022

July Newsletter 2022

25/07/2022

European PromarkerD patents expanded beyond diabetes

18/07/2022

Investor Presentation

30/06/2022

Promarker™ pipeline – Endometriosis update Diagnostic readout positive: Study expanded

28/06/2022

QIMR Berghofer Licenses Esophageal Cancer Blood Biomarkers to Proteomics International – Precision Oncology News

21/06/2022

Proteomics International (ASX:PIQ) secures licence for oesophageal cancer biomarkers – The Market Herald

21/06/2022

Proteomics International secures exclusive licence to oesophageal cancer biomarkers

16/06/2022

Pilot test kit takes Proteomics step closer to sales – The West Australian

16/06/2022

Proteomics International Laboratories (ASX:PIQ) completes PromarkerD manufacturing tech transfer – The Market Herald

16/06/2022

PromarkerD manufacturing tech-transfer completed – Successful production of components for over 50,000 tests

06/06/2022

Study boosts diagnostic potential for Proteomics – The West Australian

06/06/2022

Study shows PromarkerD ability to also predict late-stage kidney decline in type-2 diabetes patients

02/06/2022

PromarkerD registration submitted to the TGA

26/05/2022

Investor Presentation – Jefferies MedTech & Biotech summit

12/05/2022

Proteomics International awarded funding to support diabetic kidney disease test development – The Market Herald

12/05/2022

Proteomics International awarded $400,000 to support manufacturing capability in Australia

30/04/2022

April Newsletter 2022

12/04/2022

New Clinical Advisory Board to support PromarkerD global rollout – Yahoo! Finance

12/04/2022

New Clinical Advisory Board for PromarkerD global rollout

07/04/2022

Investor Presentation – Perth Healthcare Summit

24/03/2022

Indian IP win gives Proteomics massive global cover – The West Australian

24/03/2022

PromarkerD patent granted in India

10/03/2022

Investor Presentation – Euroz Hartleys Institutional Conference 2022

22/02/2022

Proteomics eyes Medicare for rebate inclusion – The West Australian

22/02/2022

PromarkerD completes ‘pre-assessment’ for Medicare rebate

07/02/2022

Novel biomarkers identified for Asthma and COPD

04/02/2022

Study results emerge for Proteomics International Laboratories’ latest cancer diagnostic test – The Sentiment

04/02/2022

Unique panel of biomarkers identified for oesophageal cancer

31/01/2022

January Newsletter 2022